Komori
Presentation materials for financial results4579RaQualia Pharma Inc.Pharmaceuticals

(Correction) Financial Results Presentation Materials for the First Quarter of the Fiscal Year Ending December 2026 (18th Fiscal Year)

The period number shown on the cover of the earnings presentation materials was corrected from the 18th fiscal period to the 19th fiscal period. This was not a correction to the financial results or earnings forecasts.

Worth reading
21Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure15 May 2026

Fiscal Year Ending December 2026 (18th Fiscal Period) First-Quarter Financial Results Briefing Materials

Open the original document
3 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-05-18
Location of correction (where in the original document)

Cover

Before correction

Fiscal Year Ending December 2026 (18th Fiscal Period), First Quarter

After correction

Fiscal Year Ending December 2026 (19th Fiscal Period), First Quarter

ChangesChanged from the 18th fiscal period to the 19th fiscal period
Reason for correction

Typographical error

What was corrected and how
ItemDetails
Disclosure subject to correctionFiscal Year Ending December 2026 (18th Fiscal Period) First-Quarter Financial Results Briefing Materials
Original disclosure date15 May 2026
Location of correctionCover
Details of correctionFiscal Year Ending December 2026 (18th Fiscal Period), First Quarter → Fiscal Year Ending December 2026 (19th Fiscal Period), First Quarter
Reason for correctionTypographical error
Items this document does not state (1)
Impact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that the materials it published on 15 May 2026 contained a typographical error.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Financial Results Presentation Materials for the First Quarter of the Fiscal Year Ending December 2026 (18th Fiscal Year) | RaQualia Pharma Inc. (4579) timely disclosure | Komori